Review ArticlesImmune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors A Systematic Review and Meta-AnalysisPetrelli, Fausto*; Grizzi, Giulia†; Ghidini, Michele‡; Ghidini, Antonio§; Ratti, Margherita†; Panni, Stefano†; Cabiddu, Mary*; Ghilardi, Mara*; Borgonovo, Karen*; Parati, Maria C.*; Tomasello, Gianluca†; Barni, Sandro*; Berruti, Alfredo∥; Brighenti, Matteo†Author Information *Oncology Unit, ASST Bergamo Ovest, Treviglio (BG) †Oncology Unit, ASST Cremona, Cremona ‡Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico §Oncology Unit, Casa di cura Igea, Milan ∥Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, Medical Oncology, University of Brescia at ASST-Spedali Civili, Brescia, Italy Reprints: Fausto Petrelli, Oncology Unit, ASST Bergamo Ovest, Piazzale Ospedale 1, Treviglio (BG) 24047, Italy (e-mail: email@example.com). Received February 14, 2019 Accepted August 26, 2019 Online date: September 30, 2019 Journal of Immunotherapy: January 2020 - Volume 43 - Issue 1 - p 1-7 doi: 10.1097/CJI.0000000000000300 Buy SDC Metrics Abstract Immune-related adverse events (irAEs) are autoimmune-toxic effects associated with immune checkpoint inhibitors (ICIs) used for the treatment of advanced solid tumors. We performed a systematic review and meta-analysis of the published literature to assess the outcome for cancer patients treated with ICIs who develop irAEs. Two independent reviewers selected prospective or retrospective studies from PubMed, EMBASE, and the Cochrane Library database from their inception to November 2018. Data were pooled using hazard ratios (HRs) for overall survival or progression-free survival or odds ratio for overall response rate of irAEs versus no irAEs according to fixed or random-effect model. HRs for OS (the primary outcome measure) were pooled to provide an aggregate value. A total of 30 studies that included a total of 4324 patients treated with ICIs were selected. Patients who developed irAEs presented a reduced risk of death [HR=0.49, 95% confidence interval (CI): 0.38–0.62; P<0.001]. Similarly, the occurrence of irAEs was associated with a reduced risk of progression (HR=0.51, 95% CI: 0.42–0.64; P<0.001). The odds of response was 4.56 (95% CI: 3.72–5.59; P<0.001). In patients treated with ICIs, irAEs predict survival and response. Although this correlation cannot be fully explained, it may be related to the strongest T-cell activation. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.